← All trials
NCT03583710
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 20, 2018
- Primary completion
- Jan 22, 2025
- Completion date
- Jan 22, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas at HoustonLead sponsor
- University of TurinOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- Amercian Australian Asian Adrenal Alliance (A5)Collaborator
- European Network for the Study of Adrenal Tumors (ENS@T)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.